ACHE and early-onset autosomal dominant Alzheimer disease: AChE inhibitors reduce AChE activity and maintain or increase ACh levels, which are typically deficient in Alzheimer’s disease (AD), and thus, enhance cholinergic transmission in brain [2,3].